Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Poria cocos (Pachymic acid).
A lanostane-type triterpenoid derived from Poria cocos that exhibits potent anti-inflammatory, anti-tumor, and sedative properties by modulating the NF-κB pathway and GABAergic signaling.
155583
249.29 g/mol
N/A
3-(ethylamino)-4-methylphenol;sulfuric acid
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Poria cocos (Pachymic acid) across standard consumer modalities.
High lipophilicity and low aqueous solubility necessitate the use of lipid-based carriers or micronization to prevent poor bioavailability in standard dry powder formats.
The hydrophobic nature of the triterpenoid structure can lead to phase separation and uneven distribution within the hydrophilic pectin or gelatin matrix.
Significant payload limitations exist due to the high dose required for therapeutic efficacy relative to the thin-film polymer matrix capacity.
Ready to launch a product featuring Poria cocos (Pachymic acid)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Poria cocos (Pachymic acid) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Poria cocos (Pachymic acid) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation